Prognostic impact of immunohistochemical and molecular genetic markers in Diffuse Large B-cell lymphoma

Aim. To evaluate impact of different clinical features on prognosis in Diffuse Large B-cell lymphoma (DLBCL) patients and to determine potential correlation between IHC markers (double-expression of c-myc, bcl-2 and p53) on unfavorable clinical characteristics in DLBCL patients.
Methods. We analyzed 215 patients with DLBCL who received treatment from 2008 to 2016. We assess impact of different clinical features, such as B-symptoms, extranodal involvement, advanced stages and refractory course on PFS. In this study we also access potentially unfavorable impact of double expression of c-myc and bcl-2 and p 53 by immunohistochemical analysis.
Results. In both uni- and multivariant analysis B-symptoms, advanced stages and primary-refractory course were identified as negative prognostic factors for PFS rates. We found tendency to correlation between double expression of c-myc and bcl-2 and high International prognostic index as well as expression of p53 and advanced stages (87,5% vs 56,4% respectively, р = 0,095).
Сonclusion. Patients with DLBCL aggressive course of the disease (B-symptoms, advanced stages and primary-refractory disease) have lower rates of PFS. Double-expression of c-myc and bcl-2 and p53 can be potentially associated with aggressive course of the disease.

Diffuse Large B-cell lymphoma (DLBCL), high-grade lymphoma, primary-refractory disease, с-myc, bcl-2, p53

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. Available at: https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21442.

2. Ferlay J., Colombet M., Soerjomataram I., Dyba T., Randi G., Bettio M., et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103: 356–387. doi: 10.1016/j.ejca.2018.07.005.

3. Cohen J.B. Novel therapies for relapsed/refractory aggressive lymphomas. Hematology Am Soc Hematol Educ Program. 2018;30:75–82. doi: 10.1182/asheducation-2018.1.75.

4. Kaprin A.D., Starinskiy V.V., Petrova G.V. (eds). Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow, 2018. (In Russ.) Available at: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.

5. Tilly H., Gomes da Silva M., Vitolo U., Jack A., Meignan M., Lopes-Guillermo A., et al. Diffuse Large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26: v116–v125. doi: 10.1093/annonc/mdv304.

6. Shipp M.A., Harrington D.P., Anderson J.R. et al. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin’s lymphoma. New England Journal of Medicine. 1993,329(14):987–994. doi: 10.1056/NEJM199309303291402.

7. Poddubnaya I.V., Savchenko V.T. et al. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. (In Russ.) Available at: http://www.hematology.ru/oncohematology/standarts/clinical_guidelines-draft.pdf.

8. Green T.M., Young K.H., Visco C., Xu-Monette Z. Y., Orazi A., et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460-3467. Available at: https://ascopubs.org/doi/10.1200/JCO.2011.41.4342.

9. Wang X.J., Medeiros L.J., Bueso-Ramos C.E., Tang G., Wang S., Oki Y., et al. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. Mod Pathol. 2017;30(2):194–203. doi: 10.1038/modpathol.2016.178.

10. Swerdlow S.H., Campo E., Pireli S.A., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer (IARC); 2016.

11. Filatova L.V., Kharchenko E.V., Alekseev S.M., Zyuzgin I.S., Artemieva A.S., Motalkina M.S., et al. Prospects for high-dose chemotherapy with autologous hematopoietic stem cell transplantation in the first line of therapy for aggressive non-Hodgkin’s lymphomas. Voprosy onkologii = Problems in oncology. 2017;63(2):326–328. (In Russ.) Available at: https://elibrary.ru/item.asp?id = 29114521.

12. Cunningham D., Hawkes E.A., Jack A., Qian W., Smith P., Mouncey P., et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. The Lancet. 2013;381(9880):1817–1826 doi: 10.1016/S0140-6736(13)60313-X.

13. Petrov S.V., Raykhlin T.N. Manual on immunohistochemical diagnostics of human tumors. Kazan’; 2012. 623 p. (In Russ.)

14. Stukov A.N. Blank M.A., Semiglazova T.Yu., Belyayev A.M. (ed.) Pharmacotherapy of tumors. Dedicated to the memory of Mikhail Lazarevich Gershanovich. St. Petersburg: Oncology issues; 2017. 512 с. (In Russ.) Available at: https://www.niioncologii.ru/science/inno/%D0%A4%D0%B0%D1%80%D0%BC%D0%B0%D0%BA%D0%BE%D1%82%D0%B5%D1%80%D0%B0%D0%BF%D0%B8%D1%8F_%D0%BE%D0%BF%D1%83%D1%85%D0%BE%D0%BB%D0%B5%D0%B9.pdf.